Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.9K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.9K
Feedback Inhibition00:46

Feedback Inhibition

57.1K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.1K
PD Controller: Design01:26

PD Controller: Design

646
In automotive engineering, car suspension systems often employ Proportional Derivative (PD) controllers to enhance performance. PD controllers are utilized to adjust the damping force in response to road conditions. A controller, acting as an amplifier with a constant gain, demonstrates proportional control, with output directly mirroring input.
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
646
Experimental RNAi02:15

Experimental RNAi

7.5K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.5K
Time-Domain Interpretation of PD Control01:07

Time-Domain Interpretation of PD Control

394
Proportional-Derivative (PD) control is a widely used control method in various engineering systems to enhance stability and performance. In a system with only proportional control, common issues include high maximum overshoot and oscillation, observed in both the error signal and its rate of change. This behavior can be divided into three distinct phases: initial overshoot, subsequent undershoot, and gradual stabilization.
Consider the example of control of motor torque. Initially, a positive...
394
Enzyme Inhibition01:30

Enzyme Inhibition

91.9K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Multifaceted Role of microRNA-10b (miR-10b) in Glioblastoma: From Oncogenic Driver to Therapeutic Target.

Cells·2026
Same author

Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy.

Molecular imaging and biology·2026
Same author

Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma Models.

Journal of functional biomaterials·2026
Same author

Biocompatibility Analysis of Thin-Film Titanium and Gold Coatings on Parylene-Insulated Glass Wires for MRI-Compatible Implantable Leads.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025
Same author

Author Correction: Manganese-based type I collagen-targeting MRI probe for in vivo imaging of liver fibrosis.

Npj imaging·2025
Same author

Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment.

Cancer research·2025

Related Experiment Video

Updated: Jan 27, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.0K

RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy.

Byunghee Yoo1, Veronica Clavijo Jordan1, Patrick Sheedy2

  • 1MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA.

Scientific Reports
|March 20, 2019
PubMed
Summary

This study introduces a novel combination therapy for pancreatic cancer using gemcitabine and a magnetic nanocarrier delivering small interfering RNA against programmed death-ligand 1 (siPDL1). This approach significantly reduced tumor growth and increased survival in mice, offering hope for this intractable disease.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K

Related Experiment Videos

Last Updated: Jan 27, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.0K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K

Area of Science:

  • Oncology
  • Nanotechnology
  • Immunotherapy

Background:

  • Immunotherapy, particularly immune checkpoint inhibitors, shows promise but has variable efficacy.
  • Pancreatic cancer remains largely resistant to current immunotherapy strategies.
  • Novel therapeutic approaches are urgently needed for pancreatic ductal adenocarcinoma.

Purpose of the Study:

  • To evaluate a novel combination therapy for pancreatic cancer.
  • To investigate the efficacy of gemcitabine combined with a magnetic nanocarrier-based programmed death-ligand 1 (PD-L1) inhibitor (MN-siPDL1).
  • To assess the potential of magnetic resonance imaging (MRI) for monitoring therapeutic response.

Main Methods:

  • A syngeneic murine pancreatic cancer model was utilized.
  • Combination therapy involved gemcitabine and MN-siPDL1 (siPDL1 conjugated to a magnetic nanocarrier).
  • Tumor volume, survival rates, and therapeutic response were monitored, with MRI used for assessment.

Main Results:

  • Combination therapy significantly reduced tumor volume by 90% within 2 weeks.
  • Survival rates dramatically increased, with 67% of treated animals surviving for 12 weeks compared to 0% in controls by week 6.
  • Noninvasive MRI successfully monitored therapeutic response.

Conclusions:

  • The combination of gemcitabine and MN-siPDL1 demonstrates significant therapeutic benefit in a preclinical pancreatic cancer model.
  • This novel nanomedicine approach offers a promising strategy against treatment-resistant pancreatic cancer.
  • The use of MRI for monitoring provides a noninvasive method to assess treatment efficacy.